aidsmap news story
A first-line antiretroviral regimen containing dolutegravir reduces a high viral load faster than one containing bictegravir, and the effect was especially noticeable in people with the highest viral load, French researchers reported at AIDS 2026.
The findings have implications for the choice of first-line regimen in people with a high viral load, and may also be important for preserving immune function and restricting the size of the HIV reservoir, Dr Antoine Chéret of the University of French West Indies told the conference.
A second study presented at AIDS 2026, the randomised In VOGUE trial, showed that dolutegravir/lamivudine (Dovato) was non-inferior to bictegravir/tenofovir alafenamide/emtricitabine (Biktarvy) in previously untreated adults with HIV.
Read the full news story here.
View all aidsmap reports from AIDS 2026
Source : aidsmap
Related HIV and Co-Infections News
-
[AIDS 2026] aidsmap: Once-weekly islatravir/lenacapavir combination pill maintains HIV viral suppression
-
[AIDS 2026] aidsmap: Islatravir plus ulonivirine shows promise for weekly oral HIV treatment
-
[AIDS 2026] aidsmap: Long-acting injectable treatment superior to daily pills for adolescents in African trial
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.